Omalizumab for urticaria study status

Home
Research News
Omalizumab for urticaria study status

Omalizumab for urticaria study status

By There are no tags

In the online edition of the “New England Journal of Medicine” the first results from the Novartis Phase III study (ASTERIA II) of the use of omalizumab for chronic sponaneous urticaria (CSU) have been published. The data were also presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting in San Antonio, Texas, USA.
Novartis claims that the results indicate that Omalizumab is a potentially valuable treatment option for moderate to severe refractory chronic idiopathic or spontaneous urticaria (CIU/CSU). Novartis aims at a regulatory submission for this new application of Omalizumab in 2013.

See NEJM site for article:
Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous Urticaria
Maurer M, Rosén K, Hsieh H-J, Saini S, Grattan C, Gimenéz-Arnau A, Agarwal S, Doyle R, Canvin J, Kaplan A, and Casale T.

See Novartis press release here.

IgE-Quantification can be used to monitor an anti-IgE therapy, like omalizumab treatment.
For example, the amount of remaining free IgE under omalizumab treatment can be quantified using PLS-Design‘s IgE-AviQuant molecule. Read more here!

There are no comments yet, but you can be the first



Comments are closed.

Copyright 2018 by PLS-Design GmbH